Physician profile
Timothy L Cocks
NPI 1154414217
$7,357.34
in general payments reported to CMS, 2019-2025
40 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $893 · 2021: $1,628 · 2022: $1,288 · 2023: $1,320 · 2024: $655 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $943.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $729.53 | 2019-2025 | Vraylar, Synthroid, Ubrelvy |
| Lilly USA, LLC | $582.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $391.87 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.06 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $326.22 | 2019-2025 | |
| Amgen INC. | $308.73 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $302.72 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $272.57 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $250.26 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.47 | 2019-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $229.15 | 2020-2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $227.76 | 2019-2023 | Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $204.61 | 2019-2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $193.92 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cocks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.